Ucinkovitost in varnost zdravila z izvleckom plodu palmeta pri bolnikih s tezavami mokrenja zaradi benignega povecanja prostate

Abstract Background: Benign prostatic enlargement (BPE) is the most frequent cause of lower uri-nary tract symptoms (LUTS) in men. The objective of this study was to evaluate the efficacy and safety of Prostasan, the plant extract of saw palmetto in men with LUTS/BPE. Methods: The study was approved...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Zdravniški vestnik (Ljubljana, Slovenia : 1992) Slovenia : 1992), 2014-01, Vol.83 (1)
Hauptverfasser: Trsinar, Bojan, Lovsin, Marko, Parac, Ivan, Kreft, Samo, Bratus, Dejan
Format: Artikel
Sprache:slv
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page
container_title Zdravniški vestnik (Ljubljana, Slovenia : 1992)
container_volume 83
creator Trsinar, Bojan
Lovsin, Marko
Parac, Ivan
Kreft, Samo
Bratus, Dejan
description Abstract Background: Benign prostatic enlargement (BPE) is the most frequent cause of lower uri-nary tract symptoms (LUTS) in men. The objective of this study was to evaluate the efficacy and safety of Prostasan, the plant extract of saw palmetto in men with LUTS/BPE. Methods: The study was approved by the Ethical Committee of the Republic of Slovenia. In a prospective, open clinical study, men between 45 and 80 years of age with at least moderate LUTS/ BPE, normal serum PSA, in a good physical condition were included aer having given their written informed consent . At the beginning of this study, the digito-rectal examination of the prostate was performed together with the evaluation of IPSS and quality of life, total PSA in serum, uroow and transabdominal US measurement of prostate volume. They were also asked about their erectile dysfunction and libido. All patients received Prostasan 320 mg per day for 12 months. The same parameters as at the beginning of the study were assessed aer 6 and 12 months. The subjective assessments of the efficacy and safety of the drug were also recorded by investigators and by patients. The side eects of the treatment were recorded at both follow-ups. For statistical analyses, t-test and chi-square tests were used. Results: 72 men out of 76 (94.7 %) with LUTS/ BPE completed the trial. They were 62.7 8.54 years old. IPSS score and quality of life were reduced from 14.46 5.36 to 11.08 3.92 (p = 0.0000) and from 2.72 0,96 to 2.25 1.05 (p = 0.0001) respectively aer 12 months of treatment. The uroow increased from 13.94 5.00 to 15.34 4.07 ml/s (p = 0.0005). Total PSA did not change signicantly. Aer 12 months, prostate volume decreased by 3 % (p = 0.0392). Prostasan had no important inuence on erectile function or libido. The majority of patients and doctors rated the efficacy of drug as good (69.7 % and 72.4 % ) and safe (86.8 % and 88.2 %), respectively. Seven patients (9.2 %) reported drug-related side eects. Conclusions: According to our 12-month clinical trial, we could conclude that Prostasan is a safe and efficient natural drug for the treatment of men with mild to moderate LUTS/BPE.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1497975470</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3217931221</sourcerecordid><originalsourceid>FETCH-proquest_journals_14979754703</originalsourceid><addsrcrecordid>eNqNjUFuwjAQRS0EElB6h5FYR3JI0iRrRNUDwBpNkymdxLGD7XiRTa9eI3EAVv9J_339hdikRZUmUh7yZeQsrRKZ5eVabJ3rpCyqj0O9EX-XhnVvAnvjPLCGgFY_cG4tBlYIM_AcFDW9GWBUpp1gRDWQRxgtw7dRmnv-BQeeZgw4MAymt6S7OEWLbXRI803TLS5MoAYf1WjjCXraidUPKkfvz3wT-8_T-fiVROE-kfPXzkxWx-qa5nVZl0Veyuw16x8VdFNf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1497975470</pqid></control><display><type>article</type><title>Ucinkovitost in varnost zdravila z izvleckom plodu palmeta pri bolnikih s tezavami mokrenja zaradi benignega povecanja prostate</title><source>DOAJ Directory of Open Access Journals</source><source>EZB Electronic Journals Library</source><creator>Trsinar, Bojan ; Lovsin, Marko ; Parac, Ivan ; Kreft, Samo ; Bratus, Dejan</creator><creatorcontrib>Trsinar, Bojan ; Lovsin, Marko ; Parac, Ivan ; Kreft, Samo ; Bratus, Dejan</creatorcontrib><description>Abstract Background: Benign prostatic enlargement (BPE) is the most frequent cause of lower uri-nary tract symptoms (LUTS) in men. The objective of this study was to evaluate the efficacy and safety of Prostasan, the plant extract of saw palmetto in men with LUTS/BPE. Methods: The study was approved by the Ethical Committee of the Republic of Slovenia. In a prospective, open clinical study, men between 45 and 80 years of age with at least moderate LUTS/ BPE, normal serum PSA, in a good physical condition were included aer having given their written informed consent . At the beginning of this study, the digito-rectal examination of the prostate was performed together with the evaluation of IPSS and quality of life, total PSA in serum, uroow and transabdominal US measurement of prostate volume. They were also asked about their erectile dysfunction and libido. All patients received Prostasan 320 mg per day for 12 months. The same parameters as at the beginning of the study were assessed aer 6 and 12 months. The subjective assessments of the efficacy and safety of the drug were also recorded by investigators and by patients. The side eects of the treatment were recorded at both follow-ups. For statistical analyses, t-test and chi-square tests were used. Results: 72 men out of 76 (94.7 %) with LUTS/ BPE completed the trial. They were 62.7 8.54 years old. IPSS score and quality of life were reduced from 14.46 5.36 to 11.08 3.92 (p = 0.0000) and from 2.72 0,96 to 2.25 1.05 (p = 0.0001) respectively aer 12 months of treatment. The uroow increased from 13.94 5.00 to 15.34 4.07 ml/s (p = 0.0005). Total PSA did not change signicantly. Aer 12 months, prostate volume decreased by 3 % (p = 0.0392). Prostasan had no important inuence on erectile function or libido. The majority of patients and doctors rated the efficacy of drug as good (69.7 % and 72.4 % ) and safe (86.8 % and 88.2 %), respectively. Seven patients (9.2 %) reported drug-related side eects. Conclusions: According to our 12-month clinical trial, we could conclude that Prostasan is a safe and efficient natural drug for the treatment of men with mild to moderate LUTS/BPE.</description><identifier>ISSN: 1318-0347</identifier><identifier>EISSN: 1581-0024</identifier><language>slv</language><publisher>Ljubljana: ZDRAVNISKI VESTNIK - SLOVENIAN MEDICAL JOURNAL</publisher><subject>Dietary supplements ; Drug therapy ; Extraction processes ; Flowers &amp; plants ; Prostate ; Urinary tract diseases</subject><ispartof>Zdravniški vestnik (Ljubljana, Slovenia : 1992), 2014-01, Vol.83 (1)</ispartof><rights>Copyright ZDRAVNISKI VESTNIK - SLOVENIAN MEDICAL JOURNAL Jan 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Trsinar, Bojan</creatorcontrib><creatorcontrib>Lovsin, Marko</creatorcontrib><creatorcontrib>Parac, Ivan</creatorcontrib><creatorcontrib>Kreft, Samo</creatorcontrib><creatorcontrib>Bratus, Dejan</creatorcontrib><title>Ucinkovitost in varnost zdravila z izvleckom plodu palmeta pri bolnikih s tezavami mokrenja zaradi benignega povecanja prostate</title><title>Zdravniški vestnik (Ljubljana, Slovenia : 1992)</title><description>Abstract Background: Benign prostatic enlargement (BPE) is the most frequent cause of lower uri-nary tract symptoms (LUTS) in men. The objective of this study was to evaluate the efficacy and safety of Prostasan, the plant extract of saw palmetto in men with LUTS/BPE. Methods: The study was approved by the Ethical Committee of the Republic of Slovenia. In a prospective, open clinical study, men between 45 and 80 years of age with at least moderate LUTS/ BPE, normal serum PSA, in a good physical condition were included aer having given their written informed consent . At the beginning of this study, the digito-rectal examination of the prostate was performed together with the evaluation of IPSS and quality of life, total PSA in serum, uroow and transabdominal US measurement of prostate volume. They were also asked about their erectile dysfunction and libido. All patients received Prostasan 320 mg per day for 12 months. The same parameters as at the beginning of the study were assessed aer 6 and 12 months. The subjective assessments of the efficacy and safety of the drug were also recorded by investigators and by patients. The side eects of the treatment were recorded at both follow-ups. For statistical analyses, t-test and chi-square tests were used. Results: 72 men out of 76 (94.7 %) with LUTS/ BPE completed the trial. They were 62.7 8.54 years old. IPSS score and quality of life were reduced from 14.46 5.36 to 11.08 3.92 (p = 0.0000) and from 2.72 0,96 to 2.25 1.05 (p = 0.0001) respectively aer 12 months of treatment. The uroow increased from 13.94 5.00 to 15.34 4.07 ml/s (p = 0.0005). Total PSA did not change signicantly. Aer 12 months, prostate volume decreased by 3 % (p = 0.0392). Prostasan had no important inuence on erectile function or libido. The majority of patients and doctors rated the efficacy of drug as good (69.7 % and 72.4 % ) and safe (86.8 % and 88.2 %), respectively. Seven patients (9.2 %) reported drug-related side eects. Conclusions: According to our 12-month clinical trial, we could conclude that Prostasan is a safe and efficient natural drug for the treatment of men with mild to moderate LUTS/BPE.</description><subject>Dietary supplements</subject><subject>Drug therapy</subject><subject>Extraction processes</subject><subject>Flowers &amp; plants</subject><subject>Prostate</subject><subject>Urinary tract diseases</subject><issn>1318-0347</issn><issn>1581-0024</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNjUFuwjAQRS0EElB6h5FYR3JI0iRrRNUDwBpNkymdxLGD7XiRTa9eI3EAVv9J_339hdikRZUmUh7yZeQsrRKZ5eVabJ3rpCyqj0O9EX-XhnVvAnvjPLCGgFY_cG4tBlYIM_AcFDW9GWBUpp1gRDWQRxgtw7dRmnv-BQeeZgw4MAymt6S7OEWLbXRI803TLS5MoAYf1WjjCXraidUPKkfvz3wT-8_T-fiVROE-kfPXzkxWx-qa5nVZl0Veyuw16x8VdFNf</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Trsinar, Bojan</creator><creator>Lovsin, Marko</creator><creator>Parac, Ivan</creator><creator>Kreft, Samo</creator><creator>Bratus, Dejan</creator><general>ZDRAVNISKI VESTNIK - SLOVENIAN MEDICAL JOURNAL</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20140101</creationdate><title>Ucinkovitost in varnost zdravila z izvleckom plodu palmeta pri bolnikih s tezavami mokrenja zaradi benignega povecanja prostate</title><author>Trsinar, Bojan ; Lovsin, Marko ; Parac, Ivan ; Kreft, Samo ; Bratus, Dejan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_14979754703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>slv</language><creationdate>2014</creationdate><topic>Dietary supplements</topic><topic>Drug therapy</topic><topic>Extraction processes</topic><topic>Flowers &amp; plants</topic><topic>Prostate</topic><topic>Urinary tract diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Trsinar, Bojan</creatorcontrib><creatorcontrib>Lovsin, Marko</creatorcontrib><creatorcontrib>Parac, Ivan</creatorcontrib><creatorcontrib>Kreft, Samo</creatorcontrib><creatorcontrib>Bratus, Dejan</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Proquest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Zdravniški vestnik (Ljubljana, Slovenia : 1992)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Trsinar, Bojan</au><au>Lovsin, Marko</au><au>Parac, Ivan</au><au>Kreft, Samo</au><au>Bratus, Dejan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ucinkovitost in varnost zdravila z izvleckom plodu palmeta pri bolnikih s tezavami mokrenja zaradi benignega povecanja prostate</atitle><jtitle>Zdravniški vestnik (Ljubljana, Slovenia : 1992)</jtitle><date>2014-01-01</date><risdate>2014</risdate><volume>83</volume><issue>1</issue><issn>1318-0347</issn><eissn>1581-0024</eissn><abstract>Abstract Background: Benign prostatic enlargement (BPE) is the most frequent cause of lower uri-nary tract symptoms (LUTS) in men. The objective of this study was to evaluate the efficacy and safety of Prostasan, the plant extract of saw palmetto in men with LUTS/BPE. Methods: The study was approved by the Ethical Committee of the Republic of Slovenia. In a prospective, open clinical study, men between 45 and 80 years of age with at least moderate LUTS/ BPE, normal serum PSA, in a good physical condition were included aer having given their written informed consent . At the beginning of this study, the digito-rectal examination of the prostate was performed together with the evaluation of IPSS and quality of life, total PSA in serum, uroow and transabdominal US measurement of prostate volume. They were also asked about their erectile dysfunction and libido. All patients received Prostasan 320 mg per day for 12 months. The same parameters as at the beginning of the study were assessed aer 6 and 12 months. The subjective assessments of the efficacy and safety of the drug were also recorded by investigators and by patients. The side eects of the treatment were recorded at both follow-ups. For statistical analyses, t-test and chi-square tests were used. Results: 72 men out of 76 (94.7 %) with LUTS/ BPE completed the trial. They were 62.7 8.54 years old. IPSS score and quality of life were reduced from 14.46 5.36 to 11.08 3.92 (p = 0.0000) and from 2.72 0,96 to 2.25 1.05 (p = 0.0001) respectively aer 12 months of treatment. The uroow increased from 13.94 5.00 to 15.34 4.07 ml/s (p = 0.0005). Total PSA did not change signicantly. Aer 12 months, prostate volume decreased by 3 % (p = 0.0392). Prostasan had no important inuence on erectile function or libido. The majority of patients and doctors rated the efficacy of drug as good (69.7 % and 72.4 % ) and safe (86.8 % and 88.2 %), respectively. Seven patients (9.2 %) reported drug-related side eects. Conclusions: According to our 12-month clinical trial, we could conclude that Prostasan is a safe and efficient natural drug for the treatment of men with mild to moderate LUTS/BPE.</abstract><cop>Ljubljana</cop><pub>ZDRAVNISKI VESTNIK - SLOVENIAN MEDICAL JOURNAL</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1318-0347
ispartof Zdravniški vestnik (Ljubljana, Slovenia : 1992), 2014-01, Vol.83 (1)
issn 1318-0347
1581-0024
language slv
recordid cdi_proquest_journals_1497975470
source DOAJ Directory of Open Access Journals; EZB Electronic Journals Library
subjects Dietary supplements
Drug therapy
Extraction processes
Flowers & plants
Prostate
Urinary tract diseases
title Ucinkovitost in varnost zdravila z izvleckom plodu palmeta pri bolnikih s tezavami mokrenja zaradi benignega povecanja prostate
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T21%3A10%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ucinkovitost%20in%20varnost%20zdravila%20z%20izvleckom%20plodu%20palmeta%20pri%20bolnikih%20s%20tezavami%20mokrenja%20zaradi%20benignega%20povecanja%20prostate&rft.jtitle=Zdravnis%CC%8Cki%20vestnik%20(Ljubljana,%20Slovenia%20:%201992)&rft.au=Trsinar,%20Bojan&rft.date=2014-01-01&rft.volume=83&rft.issue=1&rft.issn=1318-0347&rft.eissn=1581-0024&rft_id=info:doi/&rft_dat=%3Cproquest%3E3217931221%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1497975470&rft_id=info:pmid/&rfr_iscdi=true